|
FUBP3 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.2535994464713E-10 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
7.89569998271844E-09 |
| Normal-vs-Stage2 |
1.875880E-03 |
| Normal-vs-Stage3 |
7.04379887750406E-11 |
| Normal-vs-Stage4 |
7.0690120423933E-12 |
| Stage1-vs-Stage2 |
2.393400E-01 |
| Stage1-vs-Stage3 |
8.097600E-02 |
| Stage1-vs-Stage4 |
2.003500E-03 |
| Stage2-vs-Stage3 |
4.716100E-02 |
| Stage2-vs-Stage4 |
5.303100E-03 |
| Stage3-vs-Stage4 |
2.212200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.71790376263448E-11 |
| Normal-vs-AfricanAmerican |
1.060360E-02 |
| Normal-vs-Asian |
3.33819999975837E-07 |
| Caucasian-vs-AfricanAmerican |
9.012000E-02 |
| Caucasian-vs-Asian |
9.889200E-01 |
| AfricanAmerican-vs-Asian |
1.412760E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.19819999477855E-08 |
| Normal-vs-Female |
2.92630031317742E-10 |
| Male-vs-Female |
5.467000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.20719999552321E-08 |
| Normal-vs-Age(41-60Yrs) |
1.03520000349633E-08 |
| Normal-vs-Age(61-80Yrs) |
6.04200001141919E-09 |
| Normal-vs-Age(81-100Yrs) |
8.815600E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.373400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.319600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.191200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
5.449800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.769000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.149800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
4.381900E-04 |
| Classical-VS-Follicular |
1.069970E-01 |
| Classical-VS-Other |
7.460600E-01 |
| Classical-VS-Normal |
5.06270025901756E-10 |
| Tall-VS-Follicular |
8.45480000000176E-05 |
| Tall-VS-Other |
4.153400E-01 |
| Tall-VS-Normal |
3.68538533024321E-12 |
| Follicular-VS-Other |
4.428400E-01 |
| Follicular-VS-Normal |
5.160000E-04 |
| Other-VS-Normal |
8.676800E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
7.52159999839463E-08 |
| Normal-vs-N1 |
4.64780003373022E-09 |
| N0-vs-N1 |
7.629800E-02 |
|
|
